← Back to headlines
Savara Receives FDA Review Extension for Lead Drug Candidate
Savara Inc. announced that the U.S. Food and Drug Administration (FDA) has extended the review period for its lead drug candidate, potentially delaying its approval decision.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
